IGM Biosciences Inc. (IGMS) Tops Q4 EPS by 34c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 4:05 PM EDT Encouraging initial data from IGM-8444 combination with FOLFIRI; first patient dosed in randomized trial
Imvotamab to move forward into clinical studies in multiple autoimmune diseases
Initiation of Phase 1 clinical trial for targeted immunostimulatory IL-15 cytokine IGM-7354Â in patients with solid tumors
  Company to hold conference call and webcast today at 4:30 p.m. EDT  Â
MOUNTAIN VIEW, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today... More
